NCI-MATCH (Molecular Analysis for Therapy Choice), the largest precision medicine trial of its kind, achieves a milestone with the release of results from three treatment arms of the trial at the American Society of Clinical Oncology (ASCO) 2018 annual meeting. Spokespersons are available for interviews.
The new results offer findings of interest for future cancer research. They could help identify targeted treatments for patients with certain gene abnormalities regardless of their cancer type. The results are the first of a large trove of data to come from nearly 40 treatment arms in new populations of patients not yet studied in any other clinical trials.
NCI-MATCH is a signal-finding trial for adults who have solid tumors, lymphomas, or myeloma that have progressed on standard treatment or rare cancers for which there is no standard treatment. The trial was co-developed by the National Cancer Institute (NCI), part of the National Institutes of Health, and the ECOG-ACRIN Cancer Research Group, part of the NCI-sponsored National Clinical Trials Network (NCTN). ECOG-ACRIN is leading the trial.
WHO: Sub-study chairs and primary trial chairs from NCI and ECOG-ACRIN
WHAT: Patient outcomes data from NCI-MATCH
WHEN: Friday, June 1, 2:45 p.m. Abstract 2503. AZD4547 in tumors with FGFR pathway aberrations (Arm W)
Saturday, June 2, 8:00 a.m. Abstract 100. T-DM1 in tumors with HER2 gene amplification (Arm Q).
And Abstract 101. Taselisib in tumors with PIK3CA gene mutations (Arm I)
WHERE: ASCO 2018 Annual Meeting, McCormick Place, Chicago
To schedule an interview with a spokesperson about NCI-MATCH prior to or during the ASCO Annual Meeting, use the contact information above.